Source Capital’s (“Source” or “Fund”) net asset value (NAV) gained 1.86% for the quarter and 11.71% for the trailing twelve months. It captured 128.0% of the return of the balanced MSCI ACWI/Bloomberg US Agg index, the Fund’s primary illustrative benchmark, over the trailing twelve months. The Fund’s risk exposure is nearly balanced between Equities and Credit.

Third-quarter activity largely continued the events discussed in the first-half commentary. In addition to trimming positions that have benefited from their association with the AI ecosystem, we added new names in healthcare (i.e., Boston Scientific, HCA) as well as SMIDs both domestically and abroad (i.e., Core & Main and JBT Marel).

Turning to our cash position, a rising rate environment has offered the opportunity to buy short-term treasuries with yields close to 5% if one takes some liberties with rounding. In addition to taking advantage of these opportunities, the Fund has also initiated a position in Treasury Inflation-Protected Securities (TIPS), with real yields north of 3%.

Moving to corporates, spreads remain relatively tight versus Treasuries, however, given the speed at which rates have recently risen, we would be surprised if this does not cause stress somewhere in the credit market.  Rest assured, consistent with prior behavior, we will run our ruler over such opportunities if they present themselves.